when to resume tirzepatide after surgery & GLP-1 Medications: Pause & Restart – PlexusDx Resuming Mounjaro After Surgery: Your

+0.04% for placebo at 40 weeks

The platform reopens on 21 July 2026 with a fully upgraded, state-of-the-art experience

Use the remaining doses within 7 days of returning home

Tirzepatide doses Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes and Zepbound for weight loss

The most commonly reported side effects include: Nausea : Affecting 12% to 24% of patients with type 2 diabetes and 24% to 31% in weight management trials Diarrhea : 12% to 17% in diabetes trials and 18% to 23% in weight management trials Decreased appetite : 5% to 10% of patients Vomiting : 5% to 10% in diabetes trials and 8% to 12% in weight management trials Constipation : 5% to 7% in diabetes trials and 16% to 17% in weight management trials Dyspepsia : 5% to 9% of patients Abdominal pain : 5% to 9% of patients Alopecia (hair loss) : Reported in weight management trials These symptoms are typically mild to moderate in severity, occur most commonly during dose escalation, and tend to diminish over time as patients develop tolerance

Abbasinejad, MD , board-certified in Obesity Medicine, our clinic provides a comprehensive approach that combines tirzepatide with tailored lifestyle changes to help you achieve sustainable weight loss